Canada · Delayed Price · Currency is CAD Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of CAD 233.03 billion. The enterprise value is 253.42 billion.
| Market Cap | 233.03B |
| Enterprise Value | 253.42B |
Important Dates
The next confirmed earnings date is Wednesday, November 4, 2026.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Aug 17, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.14% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 27.40% |
| Float | 3.17B |
Valuation Ratios
The trailing PE ratio is 9.21 and the forward PE ratio is 11.60.
| PE Ratio | 9.21 |
| Forward PE | 11.60 |
| PS Ratio | 3.26 |
| PB Ratio | 4.85 |
| P/TBV Ratio | 10.81 |
| P/FCF Ratio | 14.14 |
| P/OCF Ratio | 8.13 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.74, with an EV/FCF ratio of 15.38.
| EV / Earnings | 10.02 |
| EV / Sales | 3.59 |
| EV / EBITDA | 6.74 |
| EV / EBIT | 7.32 |
| EV / FCF | 15.38 |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 0.63.
| Current Ratio | 0.87 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 0.80 |
| Debt / FCF | 1.85 |
| Interest Coverage | 1,566.84 |
Financial Efficiency
Return on equity (ROE) is 59.82% and return on invested capital (ROIC) is 39.22%.
| Return on Equity (ROE) | 59.82% |
| Return on Assets (ROA) | 18.73% |
| Return on Invested Capital (ROIC) | 39.22% |
| Return on Capital Employed (ROCE) | 45.35% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1.07M |
| Profits Per Employee | 378,845 |
| Employee Count | 66,700 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Novo Nordisk has paid 7.01 billion in taxes.
| Income Tax | 7.01B |
| Effective Tax Rate | 21.72% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 18.76 |
| 200-Day Moving Average | 19.20 |
| Relative Strength Index (RSI) | 31.68 |
| Average Volume (20 Days) | 17,178 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novo Nordisk had revenue of CAD 71.49 billion and earned 25.27 billion in profits. Earnings per share was 5.68.
| Revenue | 71.49B |
| Gross Profit | 58.61B |
| Operating Income | 35.02B |
| Pretax Income | 32.28B |
| Net Income | 25.27B |
| EBITDA | 37.69B |
| EBIT | 35.02B |
| Earnings Per Share (EPS) | 5.68 |
Balance Sheet
The company has 9.76 billion in cash and 30.41 billion in debt, with a net cash position of -20.65 billion.
| Cash & Cash Equivalents | 9.76B |
| Total Debt | 30.41B |
| Net Cash | -20.65B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 48.02B |
| Book Value Per Share | 10.84 |
| Working Capital | -6.59B |
Cash Flow
In the last 12 months, operating cash flow was 28.62 billion and capital expenditures -12.16 billion, giving a free cash flow of 16.46 billion.
| Operating Cash Flow | 28.62B |
| Capital Expenditures | -12.16B |
| Depreciation & Amortization | 2.63B |
| Net Borrowing | 7.80B |
| Free Cash Flow | 16.46B |
| FCF Per Share | n/a |
Margins
Gross margin is 81.99%, with operating and profit margins of 48.99% and 35.35%.
| Gross Margin | 81.99% |
| Operating Margin | 48.99% |
| Pretax Margin | 45.15% |
| Profit Margin | 35.35% |
| EBITDA Margin | 52.72% |
| EBIT Margin | 48.99% |
| FCF Margin | 23.34% |
Dividends & Yields
This stock pays an annual dividend of 0.69, which amounts to a dividend yield of 4.27%.
| Dividend Per Share | 0.69 |
| Dividend Yield | 4.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 44.64% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.14% |
| Shareholder Yield | 4.42% |
| Earnings Yield | 10.86% |
| FCF Yield | 7.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novo Nordisk has an Altman Z-Score of 4.21 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.21 |
| Piotroski F-Score | 5 |